NanoVibronix reports record Q1 revenue of $921K; operating loss $568K

ENvue Medical, Inc.

2024-Q1 EPS reported -$0.23 revenue$921,000

Q1 2024 revenue $921K, largest Q1 ever; operating loss $568K.
Cash $2.7M, inventory $2.6M; balance sheet strong.
GSA contract for VA sales effective May 1, 2024, expected to accelerate adoption.
UroShield RCT study at University of Michigan begins pilot phase (up to 30 patients).
PainShield adoption growing in VA and workers' comp markets.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.